Company Index










BeiGene
BeiGene
NEWS

Hiring Ernst & Young in the U.S. may help but won’t work without a bilateral Sino-American accord on audit documents
Apr.8 2022 04:59 AM

With listing on STAR Market, loss-making cancer-drug developer would be the first Chinese biotech to trade shares on the mainland and in Hong Kong and New York
Nov.17 2021 05:11 AM

Eleven-year-old cancer-focused Chinese biotech turned its first profit this year after three of its drugs made China’s National Reimbursement Drug List
Jun.29 2021 06:18 AM

May.10 2021 18:28 PM

Dec.3 2020 18:17 PM

Beijing-based BeiGene will take over commercialization of three cancer medicines from American biopharmaceutical giant in China as part of deal, and work to commercialize 20 more
Nov.1 2019 18:25 PM

Nov.1 2019 10:16 AM

Top 15 listings by Chinese firms have raised $28.7 billion so far this year, led by China Tower this week
Aug.10 2018 17:18 PM

After lackluster BeiGene IPO, analysts argue share prices will rise when more products hit market
Aug.8 2018 18:45 PM

Hong Kong IPO could raise nearly $1 billion, complementing drug developer’s current Nasdaq listing
Jul.30 2018 18:47 PM

U.S. biopharmaceutical firm plans to hold 5.9% of cancer-drug developer to market new treatments in Europe and America
Jul.7 2017 18:44 PM
- Feb 23, 2022 08:00 AM
- Feb 23, 2022 08:00 AM
- Feb 23, 2022 08:00 AM
MOST POPULAR
- 1After Junk Downgrade, China’s Largest Developer Announces $441 Million Bond Buyback
- 2Less Than 0.1% of Shanghai’s Hospitalized Covid Patients Develop Severe Illness, Study Shows
- 3CATL Unveils Battery That Power a Car Up to 1,000 Kilometers on One Charge
- 4China Junk Bond Selloff Enters New Phase With Record Fosun Rout
- 5China Resumes More International Flights as Crippling Covid Curbs Ease